HEMAY PHARMA：passed HKEX listing hearing, Mufemilast approved for Ps

NewTimeSpace News: Ganzhou Hemay Pharmaceutical Co., Ltd. has passed the listing hearing for the Main Board of The Stock Exchange of Hong Kong Limited, as disclosed by HKEX on 20 October 2026, with SDICSI acting as sole sponsor. Founded in 2002, the Company is a biopharmaceutical company dedicated to the discovery and development of self-discovered and self-developed small molecule drugs targeting autoimmune diseases and oncology.

According to the prospectus, as at the latest practicable date the Company had one core product, Mufemilast, and five small molecule drug candidates. Mufemilast is a self-discovered and self-developed small molecule PDE4/PDE4B inhibitor, and in September 2025 it obtained NDA approval in China for the treatment of moderate-to-severe plaque psoriasis (Ps).

The prospectus stated that, as at the latest practicable date, Mufemilast is also under review in pivotal Phase III trials for Behcet's disease (BD) and ulcerative colitis (UC). Phase II trials for atopic dermatitis (AD), psoriatic arthritis (PsA), Crohn's disease (CD) and chronic obstructive pulmonary disease (COPD) are ongoing or planned in China. The product has been granted orphan drug designation by the FDA for BD.